Loxbridge Funding Model Starts With Altermune Investment
BioWorld International Correspondent
LONDON – Big pharma may be getting more engaged in early stage deals, but the gulf between the end product of a typical academic research program and the kind of inputs that will fit into the bottom end of pharma's drug development pipeline remains an area that is badly in need of new approaches to funding.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST